In the second quarter of 2025, Lennar reported net earnings of $477 million, with net earnings per diluted share of $1.81 ($1.90 excluding mark-to-market losses on technology investments). This is a ...

MCD has an average analyst rating of buy and is -10.43% away from its mean target price of $328.75 per share Its trailing ...

Verve Therapeutics is a clinical-stage company developing genetic medicines for cardiovascular disease, with its lead program ...

Megan Graves, who has served as Chief Executive Officer of Hamilton Re since 2020, has decided to retire from the company, ...

D-Wave Quantum Inc. has recently announced a strategic partnership with Yonsei University and Incheon Metropolitan City, ...

Additionally, PureCycle plans to construct a 130-million-pound line in Antwerp, and after integrating the learnings from its ...

These developments mark significant progress for Dyne Therapeutics in its pursuit of accelerated approval for Dyne-101, ...

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced positive topline results from its phase 2 Explore-CKD trial of ...

Based on the unaudited pro forma condensed combined financial information provided in the press release, it is evident that ...

EPD has an average analyst rating of buy and is -12.79% away from its mean target price of $36.46 per share Its trailing earnings per share (EPS) is $2.67 Enterprise Products has a trailing 12 month ...

Shivanandan's appointment is expected to bring valuable perspective to Iridium's board, given her early career roots in ...

Yum! Brands, Inc. (NYSE: YUM) has announced the appointment of Chris Turner as its new Chief Executive Officer, effective ...